Research progress on financial toxicity in patients with heart failure_West China Medical Journal

Authors：

WENG Lingling ¹ , CHEN Jiazeng ¹ , LI Xuelian ² , KANG Pan ³ ,  CHENG Fengqin ¹

1. Department of Nursing, Mianyang 404 Hospital, Mianyang, Sichuan 621000, P. R. China;
2. Department of Cardiovascular Medicine, Mianyang 404 Hospital, Mianyang, Sichuan 621000, P. R. China;
3. Department of Cardiac and Vascular Surgery, Mianyang 404 Hospital, Mianyang, Sichuan 621000, P. R. China;

Corresponding?author：

CHENG Fengqin, Email: 1150364374@qq.com

Keywords：

Heart failure; financial toxicity; nursing

DOI：

10.7507/1002-0179.202405236

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Heart failure is a progressive disease with high readmission rate and long treatment duration, which impose a heavy financial burden on patients and their families. The resulting financial toxicity can also affect the health outcomes of patients. This article provides an in-depth analysis of the concept, evaluation tools, research status, hazards, influencing factors, and coping strategies of financial toxicity in patients with heart failure. Suggestions are put forward for the development of evaluation tools and the improvement of coping strategies for financial toxicity, aiming to provide a reference for the development of more scientific and effective systematic intervention strategies.

Citation： WENG Lingling, CHEN Jiazeng, LI Xuelian, KANG Pan, CHENG Fengqin. Research progress on financial toxicity in patients with heart failure. West China Medical Journal, 2024, 39(9): 1496-1500. doi: 10.7507/1002-0179.202405236 Copy

1.	李瑩瑩, 王華. 《2022 年 AHA/ACC/HFSA 心力衰竭管理指南》解讀——從新指南看治療進展. 中國心血管雜志, 2022, 27(5): 417-421.
2.	馬麗媛, 王增武, 樊靜, 等. 《中國心血管健康與疾病報告 2022》要點解讀. 中國全科醫學, 2023, 26(32): 3975-3994.
3.	Foroutan F, Rayner DG, Ross HJ, et al. Global comparison of readmission rates for patients with heart failure. J Am Coll Cardiol, 2023, 82(5): 430-444.
4.	Wang H, Chai K, Du M, et al. Prevalence and incidence of heart failure among urban patients in China: a national population-based analysis. Circ Heart Fail, 2021, 14(10): e008406.
5.	Ali HR, Valero-Elizondo J, Wang SY, et al. Subjective financial hardship due to medical bills among patients with heart failure in the united states: the 2014-2018 medical expenditure panel survey. J Card Fail, 2022, 28(9): 1424-1433.
6.	Bullock AJ, Hofstatter EW, Yushak ML, et al. Understanding patients’ attitudes toward communication about the cost of cancer care. J Oncol Pract, 2012, 8(4): e50-e58.
7.	Zafar SY, Abernethy AP. Financial toxicity, part I: a new name for a growing problem. Oncology (Williston Park), 2013, 27(2): 80-81, 149.
8.	況藝, 孫艷玲, 荊鳳, 等. 癌癥相關經濟毒性概念分析. 護理研究, 2021, 35(20): 3695-3700.
9.	Carrera PM, Kantarjian HM, Blinder VS. The financial burden and distress of patients with cancer: understanding and stepping-up action on the financial toxicity of cancer treatment. CA Cancer J Clin, 2018, 68(2): 153-165.
10.	王哲, 許惠靖, 王宇宇, 等. 經濟毒性對慢性病患者不良健康結局影響的研究進展. 護理學報, 2023, 30(17): 34-38.
11.	Altice CK, Banegas MP, Tucker-Seeley RD, et al. Financial hardships experienced by cancer survivors: a systematic review. J Natl Cancer Inst, 2016, 109(2): djw205.
12.	Wang SY, Valero-Elizondo J, Ali HJ, et al. Out-of-pocket annual health expenditures and financial toxicity from healthcare costs in patients with heart failure in the United States. J Am Heart Assoc, 2021, 10(14): e022164.
13.	de Souza JA, Yap BJ, Hlubocky FJ, et al. The development of a financial toxicity patient-reported outcome in cancer: the COST measure. Cancer, 2014, 120(20): 3245-3253.
14.	于慧會, 畢雪, 劉運泳. 中文版癌癥患者報告結局的經濟毒性量表信度和效度研究. 中華流行病學雜志, 2017, 38(8): 1118-1120.
15.	孫艷玲, 況藝, 袁瀟逸, 等. 癌癥生存者經濟毒性現狀及影響因素. 護理學雜志, 2022, 37(15): 24-27, 31.
16.	趙凌, 陳希偉, 龐兆烽, 等. 維持性血液透析患者經濟毒性現狀及影響因素的研究. 臨床護理雜志, 2023, 22(1): 6-10.
17.	張譯友, 田媛, 帕孜來提·賽登, 等. 腦卒中患者經濟毒性現狀及影響因素分析. 中國臨床護理, 2023, 15(3): 183-186.
18.	沈雅琳, 湯利萍, 曹英, 等. 輸尿管皮膚造口患者經濟毒性狀況及影響因素分析. 護理學雜志, 2022, 37(10): 26-29.
19.	Prawitz A, Garman ET, Sorhaindo B, et al. Incharge financial distress/financial well-being scale: development, administration, and score interpretation. Financ Couns Plan, 2006, 17(1): 34-50.
20.	Head BA, Faul AC. Development and validation of a scale to measure socioeconomic well-being in persons with cancer. J Support Oncol, 2008, 6(4): 183-192.
21.	Cook C, Cole G, Asaria P, et al. The annual global economic burden of heart failure. Int J Cardiol, 2014, 171(3): 368-376.
22.	Urbich M, Globe G, Pantiri K, et al. A systematic review of medical costs associated with heart failure in the USA (2014-2020). Pharmacoeconomics, 2020, 38(11): 1219-1236.
23.	Wei C, Heidenreich PA, Sandhu AT. The economics of heart failure care. Prog Cardiovasc Dis, 2024, 82: 90-101.
24.	Yu Y, Liu J, Zhang L, et al. Perceived economic burden, mortality, and health status in patients with heart failure. JAMA Netw Open, 2024, 7(3): e241420.
25.	徐澤宇, 邱恒, 姚奕婷, 等. 醫療服務價格改革對醫療服務供方行為的影響——以心力衰竭為例. 衛生軟科學, 2020, 34(10): 33-35.
26.	李洋. 沈陽市心力衰竭患者住院費用及影響因素分析. 沈陽: 沈陽醫學院, 2023.
27.	馬蘭虎, 藍慶肅, 武鋒超, 等. 鈉-葡萄糖協同轉運蛋白-2 抑制劑在射血分數保留性心力衰竭中的研究進展. 華西醫學, 2021, 36(9): 1288-1292.
28.	李勇, 高秀芳, 山纓, 等. 新四聯為基石, 優化心力衰竭藥物治療. 中華高血壓雜志, 2022, 30(10): 918-925.
29.	Gunn AH, Warraich HJ, Mentz RJ. Costs of care and financial hardship among patients with heart failure. Am Heart J, 2024, 269: 94-107.
30.	Slavin SD, Khera R, Zafar SY, et al. Financial burden, distress, and toxicity in cardiovascular disease. Am Heart J, 2021, 238: 75-84.
31.	Wideqvist M, Cui X, Magnusson C, et al. Hospital readmissions of patients with heart failure from real world: timing and associated risk factors. ESC Heart Fail, 2021, 8(2): 1388-1397.
32.	季朝紅. 213 例青年心力衰竭患者臨床資料的回顧性分析. 長春: 吉林大學, 2019.
33.	Valero-Elizondo J, Khera R, Saxena A, et al. Financial hardship from medical bills among nonelderly U.S. adults with atherosclerotic cardiovascular disease. J Am Coll Cardiol, 2019, 73(6): 727-732.
34.	Gunn AH, Pendyal A. Novel cardiovascular therapeutics and the risk of financial toxicity. Nat Rev Cardiol, 2024, 21(6): 349-350.
35.	Zhang H, Ning K, Wang J, et al. Research on the influence of patient cost-sharing on medical expenses and health outcomes: taking patients with heart failure as an example. Front Public Health, 2023, 11: 1121772.
36.	魯蓓, 馮天岳, 袁楊. “互聯網+”背景下慢性病長期用藥管理模式探討. 中國醫療保險, 2020(7): 57-60.
37.	中共中央國務院. 關于深化醫療保障制度改革的實施意見. 四川日報, 2021-05-01(4).
38.	孫潔, 黃藝飛, 羅嶼浪, 等. 惠民保可持續發展研究. 中國醫療保險, 2024(1): 29-42.
39.	陳華蝶, 丁劉蔚, 張真才. 我國醫保政策認知現狀及對策——以靖江市為例. 經濟研究導刊, 2022(27): 64-66.
40.	Kwok CS, Seferovic PM, Van Spall HG, et al. Early unplanned readmissions after admission to hospital with heart failure. Am J Cardiol, 2019, 124(5): 736-745.
41.	Lesyuk W, Kriza C, Kolominsky-Rabas P. Cost-of-illness studies in heart failure: a systematic review 2004-2016. BMC Cardiovasc Disord, 2018, 18(1): 74.
42.	Blum MR, ?ien H, Carmichael HL, et al. Cost-effectiveness of transitional care services after hospitalization with heart failure. Ann Intern Med, 2020, 172(4): 248-257.
43.	Ma C. Rehospitalisation rates and associated factors within 6 months after hospital discharge for patients with chronic heart failure: a longitudinal observational study. J Clin Nurs, 2019, 28(13/14): 2526-2536.
44.	孫佳玲, 朱麗莎, 夏梅, 等. 三元聯動護理模式在心力衰竭易損期病人中應用的研究進展. 全科護理, 2024, 22(6): 1106-1109.
45.	Edward J. Effective cost conversations: addressing financial toxicity and cost-related health literacy. Clin J Oncol Nurs, 2020, 24(2): 209-213.
46.	Yezefski T, Steelquist J, Watabayashi K, et al. Impact of trained oncology financial navigators on patient out-of-pocket spending. Am J Manag Care, 2018, 24(Suppl 5): S74-S79.
47.	Smith GH, Shore S, Allen LA, et al. Discussing out-of-pocket costs with patients: shared decision making for sacubitril-valsartan in heart failure. J Am Heart Assoc, 2019, 8(1): e010635.
48.	Cheung CK, Jones L, Lee H, et al. Anticipatory guidance: developing a patient navigation pathway to reduce the financial toxicity of cancer. Med Res Arch, 2023, 11(10): 10.18103/mra. v11i10.4582.
49.	袁瀟逸, 況藝, 阮君怡, 等. 癌癥患者費用相關健康素養的概念分析. 護士進修雜志, 2024: 1-12.

1. 李瑩瑩, 王華. 《2022 年 AHA/ACC/HFSA 心力衰竭管理指南》解讀——從新指南看治療進展. 中國心血管雜志, 2022, 27(5): 417-421.
2. 馬麗媛, 王增武, 樊靜, 等. 《中國心血管健康與疾病報告 2022》要點解讀. 中國全科醫學, 2023, 26(32): 3975-3994.
3. Foroutan F, Rayner DG, Ross HJ, et al. Global comparison of readmission rates for patients with heart failure. J Am Coll Cardiol, 2023, 82(5): 430-444.
4. Wang H, Chai K, Du M, et al. Prevalence and incidence of heart failure among urban patients in China: a national population-based analysis. Circ Heart Fail, 2021, 14(10): e008406.
5. Ali HR, Valero-Elizondo J, Wang SY, et al. Subjective financial hardship due to medical bills among patients with heart failure in the united states: the 2014-2018 medical expenditure panel survey. J Card Fail, 2022, 28(9): 1424-1433.
6. Bullock AJ, Hofstatter EW, Yushak ML, et al. Understanding patients’ attitudes toward communication about the cost of cancer care. J Oncol Pract, 2012, 8(4): e50-e58.
7. Zafar SY, Abernethy AP. Financial toxicity, part I: a new name for a growing problem. Oncology (Williston Park), 2013, 27(2): 80-81, 149.
8. 況藝, 孫艷玲, 荊鳳, 等. 癌癥相關經濟毒性概念分析. 護理研究, 2021, 35(20): 3695-3700.
9. Carrera PM, Kantarjian HM, Blinder VS. The financial burden and distress of patients with cancer: understanding and stepping-up action on the financial toxicity of cancer treatment. CA Cancer J Clin, 2018, 68(2): 153-165.
10. 王哲, 許惠靖, 王宇宇, 等. 經濟毒性對慢性病患者不良健康結局影響的研究進展. 護理學報, 2023, 30(17): 34-38.
11. Altice CK, Banegas MP, Tucker-Seeley RD, et al. Financial hardships experienced by cancer survivors: a systematic review. J Natl Cancer Inst, 2016, 109(2): djw205.
12. Wang SY, Valero-Elizondo J, Ali HJ, et al. Out-of-pocket annual health expenditures and financial toxicity from healthcare costs in patients with heart failure in the United States. J Am Heart Assoc, 2021, 10(14): e022164.
13. de Souza JA, Yap BJ, Hlubocky FJ, et al. The development of a financial toxicity patient-reported outcome in cancer: the COST measure. Cancer, 2014, 120(20): 3245-3253.
14. 于慧會, 畢雪, 劉運泳. 中文版癌癥患者報告結局的經濟毒性量表信度和效度研究. 中華流行病學雜志, 2017, 38(8): 1118-1120.
15. 孫艷玲, 況藝, 袁瀟逸, 等. 癌癥生存者經濟毒性現狀及影響因素. 護理學雜志, 2022, 37(15): 24-27, 31.
16. 趙凌, 陳希偉, 龐兆烽, 等. 維持性血液透析患者經濟毒性現狀及影響因素的研究. 臨床護理雜志, 2023, 22(1): 6-10.
17. 張譯友, 田媛, 帕孜來提·賽登, 等. 腦卒中患者經濟毒性現狀及影響因素分析. 中國臨床護理, 2023, 15(3): 183-186.
18. 沈雅琳, 湯利萍, 曹英, 等. 輸尿管皮膚造口患者經濟毒性狀況及影響因素分析. 護理學雜志, 2022, 37(10): 26-29.
19. Prawitz A, Garman ET, Sorhaindo B, et al. Incharge financial distress/financial well-being scale: development, administration, and score interpretation. Financ Couns Plan, 2006, 17(1): 34-50.
20. Head BA, Faul AC. Development and validation of a scale to measure socioeconomic well-being in persons with cancer. J Support Oncol, 2008, 6(4): 183-192.
21. Cook C, Cole G, Asaria P, et al. The annual global economic burden of heart failure. Int J Cardiol, 2014, 171(3): 368-376.
22. Urbich M, Globe G, Pantiri K, et al. A systematic review of medical costs associated with heart failure in the USA (2014-2020). Pharmacoeconomics, 2020, 38(11): 1219-1236.
23. Wei C, Heidenreich PA, Sandhu AT. The economics of heart failure care. Prog Cardiovasc Dis, 2024, 82: 90-101.
24. Yu Y, Liu J, Zhang L, et al. Perceived economic burden, mortality, and health status in patients with heart failure. JAMA Netw Open, 2024, 7(3): e241420.
25. 徐澤宇, 邱恒, 姚奕婷, 等. 醫療服務價格改革對醫療服務供方行為的影響——以心力衰竭為例. 衛生軟科學, 2020, 34(10): 33-35.
26. 李洋. 沈陽市心力衰竭患者住院費用及影響因素分析. 沈陽: 沈陽醫學院, 2023.
27. 馬蘭虎, 藍慶肅, 武鋒超, 等. 鈉-葡萄糖協同轉運蛋白-2 抑制劑在射血分數保留性心力衰竭中的研究進展. 華西醫學, 2021, 36(9): 1288-1292.
28. 李勇, 高秀芳, 山纓, 等. 新四聯為基石, 優化心力衰竭藥物治療. 中華高血壓雜志, 2022, 30(10): 918-925.
29. Gunn AH, Warraich HJ, Mentz RJ. Costs of care and financial hardship among patients with heart failure. Am Heart J, 2024, 269: 94-107.
30. Slavin SD, Khera R, Zafar SY, et al. Financial burden, distress, and toxicity in cardiovascular disease. Am Heart J, 2021, 238: 75-84.
31. Wideqvist M, Cui X, Magnusson C, et al. Hospital readmissions of patients with heart failure from real world: timing and associated risk factors. ESC Heart Fail, 2021, 8(2): 1388-1397.
32. 季朝紅. 213 例青年心力衰竭患者臨床資料的回顧性分析. 長春: 吉林大學, 2019.
33. Valero-Elizondo J, Khera R, Saxena A, et al. Financial hardship from medical bills among nonelderly U.S. adults with atherosclerotic cardiovascular disease. J Am Coll Cardiol, 2019, 73(6): 727-732.
34. Gunn AH, Pendyal A. Novel cardiovascular therapeutics and the risk of financial toxicity. Nat Rev Cardiol, 2024, 21(6): 349-350.
35. Zhang H, Ning K, Wang J, et al. Research on the influence of patient cost-sharing on medical expenses and health outcomes: taking patients with heart failure as an example. Front Public Health, 2023, 11: 1121772.
36. 魯蓓, 馮天岳, 袁楊. “互聯網+”背景下慢性病長期用藥管理模式探討. 中國醫療保險, 2020(7): 57-60.
37. 中共中央國務院. 關于深化醫療保障制度改革的實施意見. 四川日報, 2021-05-01(4).
38. 孫潔, 黃藝飛, 羅嶼浪, 等. 惠民保可持續發展研究. 中國醫療保險, 2024(1): 29-42.
39. 陳華蝶, 丁劉蔚, 張真才. 我國醫保政策認知現狀及對策——以靖江市為例. 經濟研究導刊, 2022(27): 64-66.
40. Kwok CS, Seferovic PM, Van Spall HG, et al. Early unplanned readmissions after admission to hospital with heart failure. Am J Cardiol, 2019, 124(5): 736-745.
41. Lesyuk W, Kriza C, Kolominsky-Rabas P. Cost-of-illness studies in heart failure: a systematic review 2004-2016. BMC Cardiovasc Disord, 2018, 18(1): 74.
42. Blum MR, ?ien H, Carmichael HL, et al. Cost-effectiveness of transitional care services after hospitalization with heart failure. Ann Intern Med, 2020, 172(4): 248-257.
43. Ma C. Rehospitalisation rates and associated factors within 6 months after hospital discharge for patients with chronic heart failure: a longitudinal observational study. J Clin Nurs, 2019, 28(13/14): 2526-2536.
44. 孫佳玲, 朱麗莎, 夏梅, 等. 三元聯動護理模式在心力衰竭易損期病人中應用的研究進展. 全科護理, 2024, 22(6): 1106-1109.
45. Edward J. Effective cost conversations: addressing financial toxicity and cost-related health literacy. Clin J Oncol Nurs, 2020, 24(2): 209-213.
46. Yezefski T, Steelquist J, Watabayashi K, et al. Impact of trained oncology financial navigators on patient out-of-pocket spending. Am J Manag Care, 2018, 24(Suppl 5): S74-S79.
47. Smith GH, Shore S, Allen LA, et al. Discussing out-of-pocket costs with patients: shared decision making for sacubitril-valsartan in heart failure. J Am Heart Assoc, 2019, 8(1): e010635.
48. Cheung CK, Jones L, Lee H, et al. Anticipatory guidance: developing a patient navigation pathway to reduce the financial toxicity of cancer. Med Res Arch, 2023, 11(10): 10.18103/mra. v11i10.4582.
49. 袁瀟逸, 況藝, 阮君怡, 等. 癌癥患者費用相關健康素養的概念分析. 護士進修雜志, 2024: 1-12.

Previous Article
Progress in the study of mechanisms of cardiac injury induced by infrasound
Next Article
介入式左心室輔助系統輔助高風險經皮冠狀動脈介入治療的手術配合及護理一例

West China Medical Journal

Research progress on financial toxicity in patients with heart failure

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content